Baird Reiterates Neutral Rating & $145 PT on Alexion Pharma (ALXN); 'Soliris Gets Positive CHMP Opinion in gMG'
Tweet Send to a Friend
Baird reiterates Neutral rating and $145 price target on Alexion Pharmaceuticals (NASDAQ: ALXN), as the CHMP issued a positive opinion ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
